Why participate?
Present methodological, technological, and regulatory considerations specific to antibodies during the preclinical development phase.
Training Context:
Preclinical studies aim to demonstrate proof of concept, evaluate product toxicity, and define the first dose to be administered to humans. This phase is critical to the success of the product in clinical development. The use of animals and the importance of these studies for patient safety have led to the implementation of a strict regulatory framework.
Interactive Teaching, Case Studies, Experience Sharing
R&D professionals, project managers, business developers, engineers, clinicians.
Solid knowledge in biotechnology and/or therapeutic antibodies, or completion of the “Fundamentals of therapeutic antibodies” training.
Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.
Participant satisfaction rate :
Return rate of satisfaction questionnaires :
Registering online or by e-mail is a pre-registration. We will process your request within one week:
Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.
When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.
For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr
